Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion type Assertion NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_head.
- NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion description "[Therefore, KRAS mutation testing should be performed in all individuals with the advanced CRC in order to identify the patients who will not respond to the monoclonal EGFR antibody inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_provenance.
- NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion evidence source_evidence_literature NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_provenance.
- NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion SIO_000772 24534449 NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_provenance.
- NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion wasDerivedFrom befree-2016 NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_provenance.
- NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_assertion wasGeneratedBy ECO_0000203 NP1155980.RATI8D31w3UtPBGOLoTF4JiAgSK_hym0jcEAW2cYs_xmk130_provenance.